Dual Targeting of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptor Pathways: Rationale and Clinical Applications for Non-Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Dual Targeting of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptor Pathways: Rationale and Clinical Applications for Non-Small-Cell Lung Cancer

Published:2007-02 Issue: Volume:8 Page:S79-S85
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Byers Lauren A.,Heymach John V.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference59 articles.

1. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines;Adjei;Clin Cancer Res,2001

2. Cancer Facts and Figures;American Cancer Society,2006

3. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

4. Two-versus three-drug combinations in the chemotherapy of advanced non-small-cell lung cancer;Pirker;Lung Cancer,2002

5. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a metaanalysis;Delbaldo;JAMA,2004

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Iodoquinazoline-derived VEGFR-2 and EGFRT790M dual inhibitors: Design, synthesis, molecular docking and anticancer evaluations;Bioorganic Chemistry;2024-02

2. Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis;Frontiers in Pharmacology;2024-01-09

3. New quinazoline sulfonamide derivatives as potential anticancer agents: Identifying a promising hit with dual EGFR/VEGFR-2 inhibitory and radiosensitizing activity;Bioorganic Chemistry;2023-11

4. Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study;Cancer Chemotherapy and Pharmacology;2023-07-31

5. Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance;Japanese Journal of Clinical Oncology;2023-06-03